The effect of succinylcholine on malignant hyperthermia events in susceptible swine

BMC Anesthesiology

Frank Schuster¹  Stephan Johannsen¹  Susanne Moegele¹  Thomas Metterlein²  Norbert Roewer¹  Martin Anetseder³ 

[1] Department of Anaesthesia and Critical Care, University of Wuerzburg, Oberduerrbacher Straße 6, D-97080 Wuerzburg, Germany

[2] Department of Anaesthesiology, University of Regensburg, Regensburg, Germany

[3] Department of Anaesthesia, Hospital Landshut-Achdorf, Landshut, Germany

关键词: Swine;    Halothane;    Succinylcholine;    Malignant hyperthermia;   

Others  :  816514
DOI  :  10.1186/1471-2253-14-14

 received in 2013-10-25, accepted in 2014-03-05,  发布年份 2014

【 摘 要 】

Background

While the impact of volatile anaesthetics to induce malignant hyperthermia (MH) is abundantly clear, the role of succinylcholine still remains controversial. To evaluate the influence of succinylcholine on porcine MH events, the authors investigated the hemodynamic and metabolic responses in MH susceptible (MHS) and non-susceptible (MHN) swine following either succinylcholine or halothane application alone or a combination of both substances.

Methods

With approval of the local animal care committee 27 MHS and 30 MHN pigs were anaesthetized and mechanically ventilated. Fiberoptic probes for continuous PCO₂ measurement were inserted into the femoral vein and the triceps muscle. Group A received succinylcholine 4 mg/kg, group B incremental doses of halothane (0.5, 1.0 vol%) and group C succinylcholine and halothane simultaneously. Vital signs were recorded continuously.

Results

Prior to drug application measured values did not differ between MHS and MHN. While MHN pigs did not show relevant alterations, succinylcholine, halothane and the combination of both lead to significant hemodynamic and metabolic changes in MHS swine.

Conclusions

Hemodynamic and metabolic alterations following succinylcholine were similar to halothane in MHS pigs. The combination of both pharmacological agents potentiated the observed effects. According to these results succinylcholine acted as an independent and supportive factor during onset of an MH episode.

【 授权许可】

   
2014 Schuster et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schuster F, Müller-Reible CR: [Malignant hyperthermia–diagnostics, treatment and anaesthetic management]. Anasthesiol Intensivmed Notfallmed Schmerzther 2009, 44:758-763.
• [2]Hopkins PM: Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011, 107:48-56.
• [3]Metterlein T, Schuster F, Kranke P, Roewer N, Anetseder M: In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced? Eur J Anaesthesiol 2011, 28:251-255.
• [4]Galloway GJ, Denborough MA: Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 1986, 58:447-450.
• [5]Schuster F, Johannsen S, Schneiderbanger D, Roewer N: Evaluation of suspected malignant hyperthermia events during anesthesia. BMC Anesthesiol 2013, 13:24. BioMed Central Full Text
• [6]Bandschapp O, Girard T: Malignant hyperthermia. Swiss Med Wkly 2012, 31:142.
• [7]Kunst G, Graf BM, Schreiner R, Martin E, Fink RH: Differential effects of sevoflurane, isoflurane, and halothane on Ca2+ release from the sarcoplasmic reticulum of skeletal muscle. Anesthesiology 1999, 91:179-186.
• [8]Diaz-Sylvester PL, Porta M, Copello JA: Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol 2008, 294:1103-1112.
• [9]Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB: Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010, 110:498-507.
• [10]Klingler W, Heiderich S, Girard T, Gravino E, Heffron J, Johannsen S, Jurkat-Rott K, Rüffert H, Schuster F, Snoeck M, Sorrentino V, Tegazzin V, Lehmann-Horn F: Functional and genetic characterization of clinical malignant hyperthermia crises: a multicenter study. Orphanet J Rare Dis 2014, 9:8. BioMed Central Full Text
• [11]Schuster F, Schöll H, Hager M, Müller R, Roewer N, Anetseder M: The dose–response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 2006, 102:468-472.
• [12]Metterlein T, Schuster F, Palmer E, Roewer N, Anetseder M: Succinylcholine in malignant hyperthermia: evaluation of a novel in vivo model. Muscle Nerve 2011, 44:213-216.
• [13]Hall LW, Trim CM, Woolf N: Further studies of porcine malignant hyperthermia. Br Med J 1972, 15:145-148.
• [14]Nelson TE, Jones EW, Bedell DM: Porcine malignant hyperthermia: a study on the triggering effects of succinylcholine. Anesth Analg 1973, 52:908-911.
• [15]Iaizzo PA, Wedel DJ: Response to succinylcholine in porcine malignant hyperthermia. Anesth Analg 1994, 79:143-151.
• [16]Sigg DC, Iaizzo PA: Malignant hyperthermia phenotype: hypotension induced by succinylcholine in susceptible swine. Anesthesiology 2000, 92:1777-1788.
• [17]Noronha-Blob L, Gover R, Baumgold J: Calcium influx mediated by nicotinic receptors and voltage sensitive calcium channels in SK-N-SH human neuroblastoma cells. Biochem Biophys Res Commun 1989, 162:1230-1235.
• [18]Harrison GG: Anaesthetic-induced malignant hyperpyrexia: a suggested method of treatment. Br Med J 1971, 3:454-456.
• [19]Pollock AN, Langton EE, Couchman K, Stowell KW, Waddington M: Suspected malignant hyperthermia reactions in New Zealand. Anaesth Intensive Care 2002, 30:453-461.
• [20]Antognini JF: Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 1995, 81:1038-1042.